Tumor Necrosis Factor (TNF) blocking therapy has recently been introduced as an important new class of biologic therapy for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and psoriatic arthritis. This class of drugs, currently comprised of three different agents, is being increasingly used for these around the world. Intensive clinical research is also defining new areas in which these drugs will be used in the future. These new indications for TNF-blocking therapy will increase the number of physicians using this class of drug.
This guide provides a comprehensive...